Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas

Already holding worldwide rights to the oral formulation and rest-of-world rights to intravenous vernakalant, Merck will partner with Cardiome Pharma to obtain FDA approval of IV vernakalant.